Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
St. Luke's-Roosevelt Hospital Center |
---|---|
Information provided by: | St. Luke's-Roosevelt Hospital Center |
ClinicalTrials.gov Identifier: | NCT00264251 |
The purpose of this study is to determine if, in men and women with excess abdominal fat and insulin resistance, people with HIV infection respond differently than people without HIV to interventions that typically improve body fat distribution and insulin resistance. The specific interventions are:
Condition | Intervention |
---|---|
HIV Infections Insulin Resistance Obesity |
Behavioral: Weight loss through diet and exercise Drug: Rosiglitazone insulin sensitizing agent |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Effect of Diet, Exercise and Rosiglitazone on Regional Fat and Insulin Resistance in HIV-Infected and Uninfected Men and Women |
Estimated Enrollment: | 48 |
Study Start Date: | July 2005 |
Study Completion Date: | August 2007 |
A constellation of nutritional alterations in HIV-infected patients receiving highly active antiretroviral therapies (HAART), including body fat redistribution with subcutaneous adipose tissue (SAT) wasting and visceral adipose tissue (VAT) accumulation, hyperlipidemia, and insulin resistance (IR) has been described. There is a major concern that these developments will be associated with adverse clinical outcomes related to atherosclerosis, as suggested by several case reports (Henry 1998, Behrens 1998, Gallet 1998, Vittecoq 1998). Although there are well documented associations among body fat distribution, insulin resistance, and adverse health outcomes, especially accelerated atherosclerosis, in non-HIV infected individuals, it is unclear if the relationships are affected by HIV infection, or if they reflect the same outcomes. This information is important, since understanding the interrelationships between body fat distribution and metabolism may guide the development of treatment strategies.
The specific hypotheses to be tested are:
Ages Eligible for Study: | 20 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |
St. Luke's-Roosevelt Hospital Center | |
New York, New York, United States, 10025 |
Principal Investigator: | Donald P Kotler, MD | St. Luke's-Roosevelt Hospital Center, Columbia University |
Principal Investigator: | Jeanine B Albu, MD | St. Luke's-Roosevelt Hospital Center, Columbia University |
Study ID Numbers: | SLRHC 02-117 |
Study First Received: | December 9, 2005 |
Last Updated: | October 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00264251 |
Health Authority: | United States: Institutional Review Board |
HIV Body composition Weight reduction Insulin resistance/sensitivity |
Exercise Diet Visceral adiposity |
Obesity Sexually Transmitted Diseases, Viral Metabolic Diseases Acquired Immunodeficiency Syndrome Overweight Insulin Immunologic Deficiency Syndromes Body Weight Virus Diseases Signs and Symptoms Hyperinsulinism |
HIV Infections Weight Loss Sexually Transmitted Diseases Nutrition Disorders Overnutrition Insulin Resistance Metabolic disorder Glucose Metabolism Disorders Rosiglitazone Retroviridae Infections |
RNA Virus Infections Hypoglycemic Agents Slow Virus Diseases Immune System Diseases |
Physiological Effects of Drugs Lentivirus Infections Infection Pharmacologic Actions |